Dawei Zhang
Dawei Zhang, Liaoning CN
Patent application number | Description | Published |
---|---|---|
20090197759 | METHOD FOR TREATING SATURATED ACTIVATED COKE - A method for treating saturated activated coke comprises the following steps: A) The saturated activated coke is subjected to a dehydration treatment so that the water content in the activated coke is ≦25%; B) The product obtained from step A is dried at a starting temperature of 120° C.-150° C.; C) The product obtained from step B is subjected to dry distillation and the condition of the dry distillation is that: by heating to a final temperature for the drying of 500° C.-600° C. at a speed of 4° C.-10° C./min and maintaining for 10-60 minutes, the organics adsorbed on the surface and in the pores of the activated coke is cracked, volatilized and carbonized; D) The product obtained from step C is activated and the activation condition is that: after heating to 800° C.-950° C. at 2° C.-8° C./min, a stream is supplied, wherein the weight ratio of the activated coke to the stream is 1:0.5-5 and the activation time is 0.5-2 h. The activated coke after several times of treatment can be used as the fuel. | 08-06-2009 |
20100311568 | METHOD AND APPARATUS FOR REGENERATING ACTIVATED COKE USED FOR TREATING WASTEWATER OR SEWAGE - A method for regenerating activated coke used for treating wastewater or sewage is provided. The method includes loading the activated coke to an environment under 150 to 250° C., heating the activated coke to a temperature of 700 to 850° C. for about 40 to 90 minutes; and providing a steam to the activated coke with a rate of 0.1 to 0.5 m | 12-09-2010 |
Dawei Zhang, Thousand Oaks, CA US
Patent application number | Description | Published |
---|---|---|
20090023761 | Heterocyclic compounds and their uses - Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer. | 01-22-2009 |
20090030002 | Heterocyclic compounds and their uses - Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelodysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer. | 01-29-2009 |
20090137581 | Heterocyclic compounds and their uses - Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer. | 05-28-2009 |
20090149468 | Substituted heterocyclic compounds and methods of use - The present invention relates to therapeutic diazobicyclo pyridines and their use in the treatment of arthritis, rheumatoid arthritis, psoriatic arthritis or osteoarthritis, organ transplant, acute transplant or heterograft and homograft rejection, ischemic and reperfusion injury, transplantation tolerance induction, multiple sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, lupus, graft vs. host diseases, T-cell mediated hypersensitivity diseases, contact hypersensitivity, delayed-type hypersensitivity, gluten-sensitive enteropathy, Type 1 diabetes, psoriasis, contact dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Graves' Disease, Addison's disease, autoimmune polyglandular disease, autoimmune alopecia, pernicious anemia, vitiligo, autoimmune hypopituatarism, Guillain-Barre syndrome, autoimmune diseases, glomerulonephritis, serum sickness, uticaria, respiratory allergies, asthma, hayfever, allergic rhinitis, skin allergies, scleracielma, mycosis fungoides, acute inflammatory responses, acute respiratory distress syndrome, dermatomyositis, alopecia areata, chronic actinic dermatitis, eczema, Behcet's disease, Pustulosis palmoplanteris, Pyoderma gangrenum, Sezary's syndrome, atopic dermatitis, systemic schlerosis, morphea, Type II diabetes and cancers where PKC theta or other PKC-family kinases are activated, overexpressed or facilitate tumor growth or survival of tumor cells, T cell leukemia, thymoma, T and B cell lymphoma, colon carcinoma, breast carcinoma and lung carcinoma or provides resistance to chemotherapeutic drugs. | 06-11-2009 |
20090275592 | Heterocyclic modulators of PKB - The invention relates to heterocyclic compounds of Formula I and compositions thereof useful for treating diseases mediated by protein kinase B (PKB) where the variables have the definitions provided herein. | 11-05-2009 |
20100179177 | HETEROCYCLIC COMPOUNDS AND THEIR USES - Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer. | 07-15-2010 |
20110152277 | HETEROCYCLIC COMPOUNDS AND THEIR USES - Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer. | 06-23-2011 |
20110275653 | HETEROCYCLIC COMPOUNDS AND THEIR USES - Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer. | 11-10-2011 |
20110275811 | HETEROCYCLIC COMPOUNDS AND THEIR USES - Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity. The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelodysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer. | 11-10-2011 |
20110281897 | HETEROCYCLIC COMPOUNDS AND THEIR USES - Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity. The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer. | 11-17-2011 |
20120040983 | Phthalazine Compounds as P38 Map Kinase Modulators and Methods of Use Thereof - The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein A | 02-16-2012 |
20120077851 | Urea Derivatives as Kinase Inhibitors - The present invention is directed to novel ureas, their derivatives, pharmaceutically acceptable salts, solvates and hydrates thereof which are useful for the treatment of protein kinases mediated diseases and conditions. The compounds of this invention have a general Formula (I) wherein R, R | 03-29-2012 |
20120101116 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS KINASES INHIBITORS AND METHODS OF USE THEREOF - The present invention is directed to novel quinolines and quniazolines, their derivatives, pharmaceutically acceptable salts, solvates and hydrates thereof which are useful for the treatment of protein kinases mediated diseases and conditions. The compounds of this invention have a general Formula (I) wherein R | 04-26-2012 |
20120220585 | HETEROCYCLIC COMPOUNDS AND THEIR USES - Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer. | 08-30-2012 |
20120220586 | HETEROCYCLIC COMPOUNDS AND THEIR USES - Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer. | 08-30-2012 |
20140235658 | QUINAZOLINE DERIVATIVES AS KINASES INHIBITORS AND METHODS OF USE THEREOF - The present invention is directed to novel quinazolines, their derivatives, pharmaceutically acceptable salts, solvates, prodrug, stereoisomer, tautomer, metabolite and hydrates thereof. The compounds and compositions of the present invention have protein kinases inhibitory activities and are expected to be useful for the treatment of protein kinases mediated diseases and conditions. | 08-21-2014 |
20140350050 | PYRIDINE COMPOUNDS AS INHIBITORS OF KINASE - The present invention relates to novel pyridines, their derivatives, pharmaceutically acceptable salts, solvates, entiomers, prodrugs and hydrates thereof. The compounds and compositions of the present invention have protein kinases inhibitory activities and are expected to be useful for the treatment of protein kinases mediated diseases and conditions, including hyper-proliferative disorder, ALK kinases mediated disorder, and neoplasia. | 11-27-2014 |
20150057312 | SUBSTITUTED QUINOLINES AS BRUTON'S TYROSINE KINASES INHIBITORS - The present invention is directed to novel quinolines, their derivatives, pharmaceutically acceptable salts, solvates and hydrates thereof. The compounds and compositions of the present invention have protein kinases inhibitory activities and are useful for the treatment of protein kinases mediated diseases and conditions. The disclosed substituted quinolines include Bruton's tyrosine kinase (Btk) inhibitors. | 02-26-2015 |
20150126537 | BICYCLIC COMPOUNDS AS KINASES INHIBITORS - The present invention is directed to novel bicyclic compounds, their derivatives, pharmaceutically acceptable salts, solvates and hydrates thereof. The compounds and compositions of the present invention have protein kinases inhibitory activities and are useful for the treatment of protein kinases mediated diseases and conditions. Novel bicyclic compounds disclosed herein include quinazolines and quinolines. | 05-07-2015 |
20150126539 | SUBSTITUTED AMINOQUINAZOLINES USEFUL AS KINASES INHIBITORS - The present invention is directed to novel quinazolines, their derivatives, pharmaceutically acceptable salts, solvates and hydrates thereof. The compounds and compositions of the present invention have protein kinases inhibitory activities and are expected to be useful for the treatment of protein kinases mediated diseases and conditions. | 05-07-2015 |
Dawei Zhang, Elmhurst, NY US
Patent application number | Description | Published |
---|---|---|
20090061031 | Compositions and methods for treating obesity, obesity related disorders and for inhibiting the infectivity of human immunodeficiency virus - The present invention relates to methods and pharmaceutical compositions for treating obesity or obesity-related disorders in a subject suffering from or predisposed to developing obesity or an obesity-related disorder, or for inhibiting the infectivity of HIV, by administering oleuropein, an analogue or derivative thereof, or the major metabolites of oleuropein including oleuropein aglycone, hydroxytyrosol, and elenolic acid or their analogues, or derivatives thereof, an iridoid glycoside, or a secoiridoid glycoside or analogues or derivatives thereof, or any combination of the foregoing including olive leave extract. The invention also relates to methods for screening/diagnosing a subject having, or predisposed to having obesity or a related disorder by measuring the expression profiles of an adipogenic gene selected from PPARγ2, LPL and αP2 gene and gene product, or other adipogenic, lipogenic, or lipolytic genes and gene products in an individual. The invention further provides for screening for novel oleuropein analogues. | 03-05-2009 |
20110142973 | Compositions and methods for treating obesity, obesity related disorders and for inhibiting the infectivity of human immunodeficiency virus - The present invention relates to methods and pharmaceutical compositions for treating obesity or obesity-related disorders in a subject suffering from or predisposed to developing obesity or an obesity-related disorder, or for inhibiting the infectivity of HIV, by administering oleuropein, an analogue or derivative thereof, or the major metabolites of oleuropein including oleuropein aglycone, hydroxytyrosol, and elenolic acid or their analogues, or derivatives thereof, an iridoid glycoside, or a secoiridoid glycoside or analogues or derivatives thereof, or any combination of the foregoing including olive leave extract. The invention also relates to methods for screening/diagnosing a subject having, or predisposed to having obesity or a related disorder by measuring the expression profiles of an adipogenic gene selected from PPARγ2, LPL and αP2 gene and gene product, or other adipogenic, lipogenic, or lipolytic genes and gene products in an individual. The invention further provides for screening for novel oleuropein analogues. | 06-16-2011 |
20140296141 | Compositions and Methods for Treating Obesity, Obesity Related Disorders and for Inhibiting the Infectivity of Human Immunodeficiency Virus - The present invention relates to methods and pharmaceutical compositions for treating obesity or obesity-related disorders in a subject suffering from or predisposed to developing obesity or an obesity-related disorder, or for inhibiting the infectivity of HIV, by administering oleuropein, an analogue or derivative thereof, or the major metabolites of oleuropein including oleuropein aglycone, hydroxytyrosol, and elenolic acid or their analogues, or derivatives thereof, an iridoid glycoside, or a secoiridoid glycoside or analogues or derivatives thereof, or any combination of the foregoing including olive leave extract. The invention also relates to methods for screening/diagnosing a subject having, or predisposed to having obesity or a related disorder by measuring the expression profiles of an adipogenic gene selected from PPARγ2, LPL and αP2 gene and gene product, or other adipogenic, lipogenic, or lipolytic genes and gene products in an individual. The invention further provides for screening for novel oleuropein analogues. | 10-02-2014 |
Dawei Zhang, Beijing CN
Patent application number | Description | Published |
---|---|---|
20130094409 | METHOD AND DEVICE FOR OBTAINING CARRIER INFORMATION AND CARRIER INFORMATION INDICATION - A method and device for obtaining carrier information and carrier information indication include: a user equipment obtains parameters of uplink carrier information according to the message sent by a network side in broadcast manner, or, the user equipment obtains parameters of uplink carrier information according to the preset information. Time Division Duplex wireless communication system with asymmetry uplink frequency band and downlink frequency band can be supported effectively, guard frequency band near the intersection occurred when the adjacent frequencies coexist is utilized fully, and frequency spectrum utilization rate is improved; further more, Time Division Duplex wireless communication system with unequal uplink band width and downlink band width can be supported, and the application of the Time Division Duplex system is expanded effectively. | 04-18-2013 |
Dawei Zhang, Dongcheng CN
Patent application number | Description | Published |
---|---|---|
20130137569 | Method for Preparing Catalyst Coating on Metal Base Plate - A method for preparing catalyst coating on a metal base plate comprising: thermal-spraying a layer of a-aluminum oxide nano-particles on a metal base plate using a high temperature flame powder spray gun, at a temperature of 2500-3500° C. and a pressure of 0.2-1.2 MPa; coating an aluminum sol, the weight concentration of the aluminum sol aqueous solution being 2-30%, at a pH of 0.5-4, the drying temperature being 50-150° C., the drying time being 0.5-24 hours, the calcination temperature being 200-1200° C., and the calcination time being 0.5-24 hours; immersing in an active component, the immersing temperature being 20-120° C., the duration being 0.5-24 hours, the drying temperature being 50-150° C., the drying time being 0.5-24 hours, the calcination temperature being 200-1200° C., and the calcination time being 0.5-24 hours. The method is suitable for the preparation of various catalyst coatings with active components. | 05-30-2013 |
Dawei Zhang, Guangdong CN
Patent application number | Description | Published |
---|---|---|
20140044758 | WOUND DRESSING WITH BACTERIOSTASIS AND HYGROSCOPICITY - A wound dressing with bacteriostatic and hygroscopicity, preparation method therefore, and the use thereof in preparing a product for treating chronic wounds. The dressing comprises chitosan fiber and modified cellulose fiber. | 02-13-2014 |
Dawei Zhang, Saratoga, CA US
Patent application number | Description | Published |
---|---|---|
20130203457 | METHODS AND APPARATUS FOR IMPROVING PERFORMANCE BASED ON FILTER CHARACTERISTICS - Methods and apparatus for improving operational and/or cost performance based on filter characteristics. Existing schemes for measuring filter performance are based on a worst case filter performance across a range of frequencies and temperature. Filter performance can be more accurately characterized over one or more frequency ranges. In one exemplary embodiment the frequency is characterized according to a functional (e.g., linear-average) metric. By providing more accurate representation of the reception/transmission filter performance, both network and device optimizations can aggressively manage available power and handle smaller (tighter) margins. | 08-08-2013 |
20150156636 | Carrier Aggregation Using Unlicensed Frequency Bands - Carrier aggregation using unlicensed frequency bands. A primary carrier for communication between a base station (BS) and a wireless user equipment (UE) device may be configured according to a first wireless communication technology. The primary carrier may be on a licensed frequency band. A secondary carrier for communication between the BS and the UE may also be configured according to a first wireless communication technology. The secondary carrier may be on an unlicensed frequency band. Channel conditions for each of multiple possible channels of the unlicensed frequency band may be assessed according to a second wireless communication technology as part of configuring the secondary carrier. | 06-04-2015 |
20150156693 | Device to Device Communications with Carrier Aggregation - Device-to-device (D2D) communications in conjunction with carrier aggregation. A base station (BS) may coordinate D2D communication between two wireless user equipment (UE) devices. A primary cell may be configured for communicating with each of the UEs. A secondary cell may be configured for D2D communication between the two UEs. The primary cell and the secondary cell may utilize different component carriers. Additionally, cross-carrier scheduling may be used, such that at least some control information for the secondary cell is communicated via the primary cell. | 06-04-2015 |
20150180619 | TTI Bundling for Downlink Communication - This disclosure relates to TTI bundling for downlink communication. According to one embodiment, a base station and a wireless device may establish a wireless communication link. The base station may determine to enable TTI bundling for downlink communication for at least one carrier of the wireless communication link. The base station may provide an indication to the wireless device to enable TTI bundling for downlink communication for the determined carrier(s) of the wireless communication link. The base station may subsequently transmit TTI bundle downlink communications to the wireless device via the determined carrier(s). | 06-25-2015 |
20150181514 | Virtual WLAN Interface for Cellular Data Offloading in a Wireless Device - This disclosure relates to use of WLAN virtual interfaces. According to one embodiment, a wireless device may be capable of using a WLAN chipset for user initiated WLAN communication and for cellular offloading WLAN communication. A separate WLAN virtual interface may be established for each type of WLAN communication, including a first WLAN virtual interface between the WLAN chipset and a WLAN connectivity manager executing on an application processor of the wireless device and a second WLAN virtual interface between the WLAN chipset and a cellular connectivity manager executing on the application processor. The virtual interfaces may each use a different IP address, and may either multiplex data onto a shared RF chain in a time-sharing manner or each be provided with their own RF chain to perform WLAN communication. | 06-25-2015 |
20150181638 | Radio Link Control Duplication for Carrier Aggregation - This disclosure relates to carrier aggregation using separate RLC entities for different component carriers. According to one embodiment, a base station and a wireless device may establish a primary component carrier and at least one secondary component carrier according to a first radio access technology. Separate radio link control entities may be established for the primary component carrier and the secondary component carrier. Data communicated between the base station and the wireless device may be routed by way of the primary component or the secondary component carrier based on differing characteristics of the component carriers, and the RLC entities may treat downlink data differently on the primary component carrier and the secondary component carrier based on the differing characteristics of the component carriers. | 06-25-2015 |
Dawei Zhang, Cupertino, CA US
Patent application number | Description | Published |
---|---|---|
20140314044 | Device and Method for Discovery Channel Hopping Scheme - A device and method generates a hopping scheme for mobile stations of a wireless network. The method includes receiving a number of channels N of the wireless network. The method includes generating a shuffling matrix as a function of the number of channels N, each row of the shuffling matrix being indicative of a respective one of the mobile stations, each column of the shuffling matrix being indicative of a respective broadcast time of a discovery signal in a hopping scheme. The method includes generating the hopping scheme for the mobile stations in the channels as a function of the shuffling matrix. The hopping scheme maximizes an interval between two consecutive broadcast times that any two of the mobile stations are assigned to transmit discovery signals on adjacent channels. | 10-23-2014 |
20150156635 | Systems and Methods for Carrier Aggregation Deployment and Organization in Unlicensed Bands - Described herein are systems and methods for carrier aggregation deployment and organization in unlicensed bands. A method may comprise scanning, by a transceiver within a base station, channels in a band of interest, reporting, by the transceiver, signal measurement information to the base station, cell searching, by the transceiver, channels in the band of interest, determining channel information for neighboring each channel, and transmitting, by the transceiver, the channel information to the base station. | 06-04-2015 |
20150156695 | Systems and Methods for Cross-Cell Carrier Aggregation for Coverage Balance Improvement - A system and methods that are performed by a macro cell and a user equipment (UE) to implement a carrier aggregation mode in a network. The system includes a macrocell including a first coverage area and a plurality of small cells, each of the small cells including a second coverage area wherein the plurality of second coverage areas substantially cover the first coverage area. The macro cell operates a first component carrier as a primary component carrier in a carrier aggregation enabled network and one of the small cells operates a second component carrier as a secondary component carrier in the carrier aggregation enabled network. | 06-04-2015 |
Dawei Zhang, Shenyang CN
Patent application number | Description | Published |
---|---|---|
20140332362 | DESTRUCTIVE DISTILLATION APPARATUS - The present invention discloses a destructive distillation apparatus, comprising a destructive distillation drum; a feeding drum and a discharge drum, respectively located at each of two ends of the destructive distillation drum. The destructive distillation drum has a larger diameter than the feeding drum and the discharge drum. An inner wall of the destructive distillation drum is installed with rows of tripper and guiding plates, and a spacing is kept between every two adjacent rows of the tripper and guiding plates. Each row of the tripper and guiding plates are consisted of a plurality of tripper and guiding plates, and each tripper and guiding plate is formed by a flat plane and a triangle having a slope. The flat planes of each row of the tripper and guiding plates are horizontally arranged, and a pointed end of the triangle is directed toward a discharge port of the destructive distillation drum. The destructive distillation drum is placed into a combustion chamber. Outer walls of the feeding drum and the discharge drum each are mounted with supporting roller rings, which are situated onto supporting rollers. An outer wall of the discharge drum is provided with a drive gear ring, which is driven by an electric motor so as to forwards or backwards rotate with the destructive distillation drum and the feeding drum. The present invention can control and adjust processing times of the materials in the destructive distillation drum during each process flow and the whole flow, so as to control product quality. | 11-13-2014 |
20140353137 | METHOD AND DEVICE FOR REMOVING DUST AND COOLING FOR ACTIVE COKE REGENERATION APPARATUS - The present invention discloses a dust removing and coding method for an active coke regeneration apparatus. When the active coke regeneration apparatus is operating, the method includes the following: generating two negative pressure regions respectively at a discharge end and a feeding end; sucking out leaked vapour and dust by means of the negative regions; and cooling down the active coke regeneration apparatus by using gas flow generated by the negative pressure. Moreover, the present invention provides a device for implementing the method as described above. | 12-04-2014 |
20150174519 | ACTIVE COKE REGENERATION MIXED VAPOR TREATMENT METHOD AND APPARATUS - There is provided an active coke regeneration mixed vapor treatment method. The method comprises the following process steps of: A) performing a first water condensation on a mixed vapor produced during an active coke regeneration process by spray water in a first condensation zone; B) performing a second water condensation on the mixed vapor that is after the first water condensation by spray water in a second condensation zone, to further condensate and purify the mixed vapor; C) eliminating moisture in a gas through mist elimination from the gas fraction in the mixed vapor that is after the second water condensation, and discharging the remaining gas from the upper of the second condensation zone; and, D) discharging active coke micro powder in the mixed vapor that is after the second water condensation, with condensation water. In the present invention, an apparatus for implementing the abovementioned method is also provided. | 06-25-2015 |
Dawei Zhang, Thousand, CA US
Patent application number | Description | Published |
---|---|---|
20150045361 | HETEROCYCLIC COMPOUNDS AND THEIR USES - Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer. | 02-12-2015 |
Dawei Zhang, Shenyang, Liaoning CN
Patent application number | Description | Published |
---|---|---|
20150174519 | ACTIVE COKE REGENERATION MIXED VAPOR TREATMENT METHOD AND APPARATUS - There is provided an active coke regeneration mixed vapor treatment method. The method comprises the following process steps of: A) performing a first water condensation on a mixed vapor produced during an active coke regeneration process by spray water in a first condensation zone; B) performing a second water condensation on the mixed vapor that is after the first water condensation by spray water in a second condensation zone, to further condensate and purify the mixed vapor; C) eliminating moisture in a gas through mist elimination from the gas fraction in the mixed vapor that is after the second water condensation, and discharging the remaining gas from the upper of the second condensation zone; and, D) discharging active coke micro powder in the mixed vapor that is after the second water condensation, with condensation water. In the present invention, an apparatus for implementing the abovementioned method is also provided. | 06-25-2015 |